Cell line · CVCL_1783
UM-UC-3
Cancer cell line, Homo sapiens. Bladder carcinoma. 81 papers.
4 sourcescell-lines-2026-11-14-0.1.0
Download JSON
Cite this record
ConductScience Library. UM-UC-3. Cell lines, record CVCL_1783. Release cell-lines-2026-11-14-0.1.0, 14 Nov 2026. https://conductscience.org/library/cell-lines/CVCL_1783
On this page
Cell line
As Cellosaurus gives it.
- Name
- UM-UC-3
- Accession
- CVCL_1783
- RRID
- RRID:CVCL_1783
- Synonyms
- UMUC-3, UM-UC3, UMUC3, UC-3, University of Michigan-Urothelial Carcinoma-3
- Species
- Homo sapiens (Human)
- Sex
- Male
- Age at sampling
- Age unspecified
- Category
- Cancer cell line
- Diseases
- Bladder carcinoma (NCIt C4912)
- Derived from
- Urinary bladder (in situ)
- Entry created
- 2012-04-04
- Entry updated
- 2026-06-25
Source Cellosaurus
Problems0
Cellosaurus records no problem for this cell line.
None in this release.
Papers81
| Paper | Journal | Year | How we know | Retracted | Source |
|---|---|---|---|---|---|
| An MMP-14/STAT3 feedback loop upregulates PD-L1 to drive immunosuppression and tumorigenesis in bladder cancer. | iScience | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Capsaicin enhances chemosensitivity and mitigates MMP11-driven aggressiveness in human bladder cancer. | Cancer Cell Int | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Isocyanate-Modified Melatplatin(IV) Enhances Antitumor Efficacy via TCF4/COL6A3-Mediated Extracellular Matrix Remodeling and cGAS-STING Pathway Activation in Bladder Cancer. | Adv Sci (Weinh) | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Enfortumab vedotin induces immunogenic cell death and shows enhanced preclinical antitumor activity when combined with a PD-1 inhibitor. | Cell Rep Med | 2026 | Its Methods give the RRID and name the line | PubMed | |
| An Integrin β6-Targeted Antibody-Drug Conjugate Optimized for Intravesical Delivery to Treat Non-Muscle-Invasive Bladder Cancer. | Mol Cancer Ther | 2026 | Its Methods give the RRID and name the line | PubMed | |
| TIMP1 Derived from Mesenchymal Stem Cells Promotes Bladder Cancer Progression by Regulating the Formation of VDIMs through the RAP1 Pathway. | Int J Biol Sci | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Targeting TPX2-dependent lineage plasticity by CDK4/6 inhibition reverses therapy resistance in neuroendocrine bladder carcinoma. | Cell Rep Med | 2026 | Its Methods give the RRID and name the line | PubMed | |
| The bladder cancer m6A landscape is defined by global methylation dilution and focal 3'-UTR hypermethylation. | EMBO Rep | 2026 | Its Methods give the RRID and name the line | PubMed | |
| HOXB4 Promotes Bladder Cancer Progression in Part Through Transcriptional Activation of Smoothened. | FASEB J | 2026 | Its Methods give the RRID and name the line | PubMed | |
| piR-43452 suppresses bladder cancer progression and enhances gemcitabine sensitivity via GTSF1/PIWIL4-mediated LRP1 mRNA destabilization. | Transl Oncol | 2026 | Its Methods give the RRID and name the line | PubMed |
1 to 10 of 81
See all 81 papersRelatives6
| Relation | Cell line | Accession | Problem | Source |
|---|---|---|---|---|
| Derived from it | EDITGENE UM-UC-3-Cas9 | CVCL_F5QN | Cell lines | |
| Derived from it | EDITGENE UM-UC-3-CopGFP | CVCL_F6BU | Cell lines | |
| Derived from it | EDITGENE UM-UC-3-FLUC | CVCL_F5UB | Cell lines | |
| Derived from it | HyCyte UM-UC-3 KO-hPRDM1 | CVCL_F4G6 | Cell lines | |
| Derived from it | UM-UC-3 LLWO1 | CVCL_A5WS | Cell lines | |
| Derived from it | UM-UC-3-Luc | CVCL_VL56 | Cell lines |
Cell banks7
| Cell bank | Catalog number | Status | Source |
|---|---|---|---|
| ATCC | CRL-1749 | ATCC | |
| CLS | 305074 | CLS | |
| CancerTools | 160434 | CancerTools | |
| ECACC | 96020936 | Discontinued | Cellosaurus |
| EDITGENE | EDC00239 | EDITGENE | |
| Hysigen | TCH-C369 | Hysigen | |
| KCB | KCB 2014053YJ | Cellosaurus |
Data dates
The date of each source this release read.
Sources 4
- CellosaurusCC BY 4.0, with credit to Cellosaurus (SIB)
- PubMed Central's articlesTitles shown only for CC0, CC BY and public domain articles
- NLM's PMC Article DatasetsCourtesy of NLM, which does not endorse this database
- PubMedNLM's terms
Each source's terms
- CellosaurusCC BY 4.0. Cellosaurus's README: "we have chosen to apply the Creative Commons Attribution 4.0 International (CC BY 4.0) license to Cellosaurus (https://creativecommons.org/licenses/by/4.0/). This means that you are free to copy and redistribute Cellosaurus in any medium or format. You can remix, transform, and build upon Cellosaurus for any purpose, even commercially. You must give appropriate credit, provide a link to the license, and indicate if changes were made." Copyright (c) CALIPHO group, SIB Swiss Institute of Bioinformatics. Read on 14 Nov 2026 at https://ftp.expasy.org/databases/cellosaurus/README
- PubMed Central's articlesEach article's own license. Its words show only under CC0, CC BY or public domain
- NLM's PMC Article DatasetsNLM's PMC Article Datasets on AWS, https://registry.opendata.aws/ncbi-pmc. Its terms: users "acknowledge NLM as the source of the data in a clear and conspicuous manner", do not use the PubMed Central wordmark or the PMC logo, do not "indicate or imply that NLM/NIH/HHS has endorsed" a product, and "only distribute data that are licensed for redistribution". Each article keeps its own license: https://pmc.ncbi.nlm.nih.gov/about/copyright/
- PubMedNLM's terms
Cellosaurus, SIB Swiss Institute of Bioinformatics, https://www.cellosaurus.org, CC BY 4.0. Its problem notes are given in its own words.
For software
Read this cell line from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/cell-lines/v1/CVCL_1783
GET https://conductscience.org/api/cell-lines/v1/CVCL_1783/papers?page=2